Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Congenital amegakaryocytic thrombocytopenia is a rare inherited bone marrow failure syndrome primarily caused by MPL gene mutations. It presents with severe neonatal thrombocytopenia and typically progresses to pancytopenia. We report the first disease-associated case of the MPL variant c.23T>G, identified through whole-exome sequencing in an infant diagnosed with congenital amegakaryocytic thrombocytopenia. Based on ACMG criteria, we propose classification of the MPL c.23T>G (p.M8R) variant as likely pathogenic. This case highlights the importance of early genetic testing in infants with unexplained thrombocytopenia and emphasizes the need to distinguish congenital amegakaryocytic thrombocytopenia from other inherited bone marrow failure syndromes. : The authors have confirmed clinical trial registration is not needed for this submission.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12393060 | PMC |
| http://dx.doi.org/10.1002/jha2.70136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Congenital amegakaryocytic thrombocytopenia is a rare inherited bone marrow failure syndrome primarily caused by MPL gene mutations. It presents with severe neonatal thrombocytopenia and typically progresses to pancytopenia. We report the first disease-associated case of the MPL variant c.
View Article and Find Full Text PDFpromoter mutation: a familial study on congenital amegakaryocytic thrombocytopenia.
J Genet
May 2025
Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare inherited bone marrow failure syndrome, which is characterized by a severe thrombocytopenia at birth without predictive stigmata and by a risk for progression into aplastic anaemia and myeloid malignancy. While CAMT primarily arises from mutations in the gene, recent discoveries have linked biallelic mutations to some CAMT cases. In addition, loss of function monoallelic mutations in this gene have been identified as causing benign autosomal dominant thrombocytopenia.
View Article and Find Full Text PDFFetal Intracranial Hemorrhage due to Uniparental Disomy and Unmasked MPL-Related Congenital Amegakaryocytic Thrombocytopenia.
Prenat Diagn
December 2024
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, California, USA.
A Rare THPO Gene Mutation in a Saudi Female Child: A Case Report and Literature Review.
Cureus
September 2024
Pediatrics Genetics, Armed Forces Hospital Southern Region, Khamis Mushait, SAU.
Thrombopoietin (THPO) is a regulator of megakaryopoiesis and thrombopoiesis. Mutation of the gene is known to cause congenital amegakaryocytic thrombocytopenia (CAMT2), which is a rare inherited disorder characterized by early infancy thrombocytopenia and absent or decreased megakaryocytes with gradual progression to pancytopenia. We report the case of a Saudi girl who had been asymptomatic until age seven when she was found to have unexplained thrombocytopenia.
View Article and Find Full Text PDFOutcomes of patients undergoing allogeneic haematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia; a study on behalf of the PDWP of the EBMT.
Bone Marrow Transplant
December 2024
Department of Paediatric Haematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.
Congenital amegakaryocytic thrombocytopenia is a rare, inherited bone marrow failure syndrome. Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. In this retrospective study, we analysed 66 patients with allo-HSCT, reported in the European Society for Blood and Marrow Transplantation (EBMT) registry.
View Article and Find Full Text PDF